The Swiss economy, renowned for its competitiveness and innovation, faces unprecedented challenges as US-imposed tariffs of 39% on Swiss goods take a heavy toll. Despite Switzerland’s significant contributions to the US economy, including creating 400,000 jobs through investments, President Trump’s trade policies have left the Alpine nation grappling with economic setbacks. Swiss President Karin Keller-Sutter’s efforts to negotiate a reduction in tariffs have so far proven futile, leaving Swiss exporters in a precarious position. Approximately 17% of Swiss exports, valued at billions, are destined for the US market, making the tariffs a severe blow to key industries. While pharmaceuticals, Switzerland’s most lucrative export to the US, remain unaffected for now, the threat of a 100% tariff on imported medicines looms large. The medical technology sector, a global leader in precision engineering, is also at risk. Companies like MPS, which produce advanced medical devices, face immense pressure as the tariffs erode already slim profit margins. Swiss business leaders argue that the tariffs are not only unjustified but also counterproductive, potentially driving up costs for US patients and taxpayers. Despite the challenges, Switzerland is actively diversifying its trade partnerships, securing agreements with India, Mercosur, and China, while maintaining its strong ties with the EU. The long-term impact of the tariffs extends beyond economics, straining the historically robust business relations between Switzerland and the US. While Swiss entrepreneurs remain hopeful for a resolution, the current administration’s approach has left many disillusioned. As Switzerland navigates this trade storm, its resilience and adaptability will be put to the test.